Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.

IF 1.7 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

European Journal of Hybrid Imaging Pub Date : 2023-04-03 DOI:10.1186/s41824-023-00165-6

Sai Duriseti, Gholam Berenji, Sonny Tsai, Matthew Rettig, Nicholas G Nickols

{"title":"Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.","authors":"Sai Duriseti, Gholam Berenji, Sonny Tsai, Matthew Rettig, Nicholas G Nickols","doi":"10.1186/s41824-023-00165-6","DOIUrl":null,"url":null,"abstract":"Rationale: Prostate cancer treatment response may be automatically quantified using a molecular imaging analysis platform targeting prostate-specific membrane antigen (PSMA).Methods: A retrospective analysis of patients with castration-sensitive prostate cancer who underwent PSMA-targeted molecular imaging prior to and 3 months or more after treatment was conducted. Disease burden was analyzed with aPROMISE, an artificial intelligence imaging platform that automatically quantifies PSMA-positive lesions. The calculated PSMA scores for prostate/bed, nodal, and osseous disease sites were compared with prostate-specific antigen (PSA) values.Results: Of 30 eligible patients, the median decline in prostate/bed, nodal, and osseous disease PSMA scores were 100% (range 52-100%), 100% (range - 87-100%), and 100% (range - 21-100%), respectively. PSMA score decline was significantly associated with PSA decline.Conclusion: Changes in aPROMISE PSMA scores are associated with changes in PSA and may quantify treatment response.","PeriodicalId":36160,"journal":{"name":"European Journal of Hybrid Imaging","volume":"7 1","pages":"7"},"PeriodicalIF":1.7000,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068685/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Hybrid Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41824-023-00165-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Rationale: Prostate cancer treatment response may be automatically quantified using a molecular imaging analysis platform targeting prostate-specific membrane antigen (PSMA).

Methods: A retrospective analysis of patients with castration-sensitive prostate cancer who underwent PSMA-targeted molecular imaging prior to and 3 months or more after treatment was conducted. Disease burden was analyzed with aPROMISE, an artificial intelligence imaging platform that automatically quantifies PSMA-positive lesions. The calculated PSMA scores for prostate/bed, nodal, and osseous disease sites were compared with prostate-specific antigen (PSA) values.

Results: Of 30 eligible patients, the median decline in prostate/bed, nodal, and osseous disease PSMA scores were 100% (range 52-100%), 100% (range - 87-100%), and 100% (range - 21-100%), respectively. PSMA score decline was significantly associated with PSA decline.

Conclusion: Changes in aPROMISE PSMA scores are associated with changes in PSA and may quantify treatment response.

Abstract Image

查看原文本刊更多论文

使用用于疾病识别和测量的自动成像平台定量评估PSMA PET对去势敏感前列腺癌治疗的反应。

理由:前列腺癌治疗反应可以使用靶向前列腺特异性膜抗原(PSMA)的分子成像分析平台自动量化。方法:回顾性分析去势敏感前列腺癌患者在治疗前及治疗后3个月及以上接受psma靶向分子显像的患者。使用aPROMISE(一种自动量化psma阳性病变的人工智能成像平台)分析疾病负担。计算的前列腺/床、淋巴结和骨性疾病部位的PSMA评分与前列腺特异性抗原(PSA)值进行比较。结果:在30例符合条件的患者中，前列腺/床、淋巴结和骨性疾病PSMA评分的中位下降分别为100%(范围52-100%)、100%(范围87-100%)和100%(范围21-100%)。PSMA评分下降与PSA下降显著相关。结论:aPROMISE PSMA评分的变化与PSA的变化相关，可以量化治疗反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊